Gilead joins the in vivo cell therapy race with $350M buyout of Interius

Gilead’s cell therapy subsidiary Kite Pharma is going in vivo with a $350 million purchase of Interius BioTherapeutics. The deal, which was announced Thursday, makes Gilead the latest drugmaker to buy ...